Hone Basic packages NAD access within a broader membership, while CoreAge advertises a NAD offer without a separate membership fee. The difference is both financial and practical: the included services need to be understood before the totals are compared.
CoreAge is this publication’s featured commercial partner. Hone’s additional services are neither an automatic disadvantage nor proof that NAD treatment works better; they are features to evaluate against your own care needs.
Hone’s listed NAD medication and Basic membership total $190/month before optional consultations. Evaluate the broader services separately from the medication and its evidence.
Hone’s medication and membership are separate
Hone’s Basic help page lists an estimated $165/month NAD medication cost, a $25/month membership, and a $25 one-time onboarding fee. The listed medication plus membership therefore totals $190/month before optional services.
The $50 due at membership signup is the membership and onboarding charge, not the entire first NAD bill. Request a written medication quote and payment schedule before treating a signup figure as the full cost.
Included labs do not mean included live consultations
Hone Basic describes lab orders every six months within the membership. Its live consultations are separate: the page lists $75 for men’s Basic and $100 for women’s Basic, with a purchase window after results.
A lab panel, a prescription review, and a live discussion are different services. Ask which you actually want and whether the membership’s broader testing is relevant to your circumstances rather than judging the plan by its feature count.
Ask what CoreAge’s included review covers
CoreAge’s NAD offer describes physician review and messaging without a membership fee. Confirm whether the selected plan offers the kind of clinical conversation you need and which additional evaluation, if any, is separate.
The CoreAge review addresses its public price discrepancy. The Hone review explains the membership model. A simpler bill can still require careful questions about access and follow-up.
A broader health platform does not prove NAD efficacy
Hone’s labs and other treatment programs should not be presented as evidence that its NAD preparation improves energy, cognition, or longevity. CoreAge’s focused offer has the same obligation to distinguish proposed benefits from established outcomes.
Ask which study supports the exact route and goal under discussion. The evidence guide explains why a biomarker result and a meaningful clinical improvement are separate findings.
Which practical preference drives the choice
Someone who wants a broader membership with periodic lab orders may investigate Hone’s structure further. Someone seeking a focused NAD evaluation may find CoreAge’s offer easier to compare. Both choices still depend on clinical suitability, state eligibility, pharmacy identity, and the actual final bill.
Before enrolling, identify which charges continue when medication stops. A membership can remain active even when a particular prescription is no longer part of the plan.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Hone: Basic membership and medication costs Provider lists $165/month estimated NAD+ cost, $25/month membership, and a $25 onboarding fee. Optional consultation fees are separate.
- CoreAge Rx: current NAD+ offer Provider advertising; offer page displays $99/month. Checked September 19, 2026.
- CoreAge Rx: NAD+ Injectable product page Provider advertising; product page displays a different starting price of $93/month.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
- Grant et al. (2019): NAD+ infusion metabolome pilot Small human IV study; metabolic observations do not prove longevity or everyday benefits.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.